サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1736417

C型肝炎検査の世界市場規模：検査キット別、手法別、エンドユーザー別、地域範囲別および予測

Global Hepatitis C Testing Market Size By Test Kits (Hepatitis C Antibody Test, Hepatitis C RNA Quantitative Test), By Technique (Immunoassays, Polymerase Chain Reaction), By End-User (Hospitals, Clinics), By Geographic Scope And Forecast

出版日
ページ情報
英文 202 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.83円
C型肝炎検査の世界市場規模：検査キット別、手法別、エンドユーザー別、地域範囲別および予測
出版日: 2025年05月02日
発行: Verified Market Research
ページ情報: 英文 202 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

C型肝炎検査の市場規模と予測

C型肝炎検査市場規模は、2024年に14億8,000万米ドルと評価され、2026～2032年にかけてCAGR 7.50%で成長し、2032年には25億1,000万米ドルに達すると予測されます。

  • C型肝炎検査は、C型肝炎ウイルス（HCV）感染を管理するための重要な要素です。HCVは血液を介して感染するウイルスで、放置すると重篤な肝障害を引き起こす可能性があります。
  • HCV感染は、抗ウイルス薬によって高度に治療可能です。効果的な治療は治癒につながり、肝疾患の進行を防ぐことができます。
  • 肝硬変や肝がんなどの合併症を防ぐには、早期診断と治療が不可欠です。
  • 米国疾病予防管理センター（CDC）によると、C型肝炎患者の3人に1人近くが自分の感染状態に気づいていないです。
  • CDCは、18歳以上のすべての成人と妊娠中のすべての人に、妊娠期間中の普遍的なC型肝炎スクリーニングを推奨しています。
  • CDCは、特定のハイリスクグループの人々をより頻繁に検査することを推奨しています。

C型肝炎検査の世界市場力学

世界のC型肝炎検査市場を形成している主要市場力学は以下の通りです。

主要市場促進要因

  • C型肝炎の有病率の上昇：C型肝炎ウイルス（HCV）感染の有病率の増加が検査需要を促進しています。世界保健機関（WHO）によると、2023年には推定5,800万人が慢性HCV感染症に罹患しています。この高い有病率は、広範な検査と早期診断の緊急の必要性を強調しています。
  • 啓発とスクリーニングプログラムの拡大啓発キャンペーンとスクリーニングプログラムの拡大がC型肝炎検査市場の成長を促進しています。米国疾病予防管理センターは、2020～2023年にかけてHCV検査率が32%増加すると報告しています。こうした取り組みは、未診断の症例を特定し、さらなる感染を防ぐために極めて重要です。
  • ポイントオブケア検査の動向：迅速なポイントオブケア検査へのシフトは、C型肝炎検査の状況を支配しています。米国食品医薬品局は2023年に3つの新しいHCVポイントオブケア検査を承認しており、このアプローチの重要性が高まっていることを示しています。これらの検査は、より迅速な診断と治療開始を可能にします。
  • 診断技術の進歩：技術の進歩がC型肝炎検査法の革新を後押ししています。米国国立衛生ラボによると、HCV検査を含む世界の分子診断市場は、2026年までに318億米ドルに達すると予測されています。こうした技術革新により、検査の精度と効率が向上しています。

主要課題

  • 限られた認識とスティグマが検査率を阻害しています。HCV感染リスクのある人の多くは、症状や検査の重要性を認識していない可能性があります。また、HCV感染にまつわるスティグマが、検査や治療を受けることを躊躇させることもあります。
  • 検査施設へのアクセス不足が早期診断を妨げる：検査施設の利用可能性が限られているため、特に十分なサービスを受けていない地域では、HCV感染の早期診断が妨げられる可能性があります。その結果、治療が遅れ、合併症のリスクが高まる可能性があります。
  • 検査と治療へのアクセスを妨げる費用の壁：HCVの検査と治療にかかる費用は、多くの人々、特に低所得者層にとって大きな障壁となりえます。そのため、治療へのアクセスが制限され、早期診断・治療が妨げられる可能性があります。
  • 市場拡大を阻む複雑な規制状況：HCV検査・治療に関する規制状況の把握は、特に複数の地域で事業を展開するヘルスケアプロバイダや製造業者にとって複雑なものとなります。規制要件の遵守はコスト増となり、市場拡大の妨げとなります。

主要動向

  • C型肝炎撲滅活動への注目の高まり：C型肝炎撲滅に向けた世界の取り組みが、検査イニシアチブの拡大を後押ししています。世界保健機関（WHO）は、2023年の時点で21カ国が2030年までにHCV排除を達成する見込みであると報告しています。このような排除プログラムが大規模検査の需要を後押ししています。
  • プライマリケアにおけるHCV検査の統合の拡大：プライマリケアにおけるC型肝炎検査の統合は急速に進んでいます。欧州疾病予防管理センターは、2021～2023年にかけてプライマリケア施設でのHCV検査が45%増加すると報告しています。この動向は、検査と早期診断へのアクセスを改善しています。
  • 政府のイニシアティブと資金調達の推進：政府の取り組みと資金提供の増加がC型肝炎検査市場を前進させています。米国保健社会福祉省は、2024会計年度にウイルス性肝炎の予防と治療のために3億9,000万米ドルを割り当てており、これは2023年から15%の増加です。こうした投資は、検査プログラムを拡大する上で極めて重要です。
  • マルチプレックス検査プラットフォームの採用増加：複数の肝炎ウイルスを同時に検出するためのマルチプレックス検査プラットフォームの採用が増加しています。National Center for BIoTechnology Informationによると、肝炎検査を含む世界のマルチプレックス診断市場は、2023年に39億米ドルと評価されました。このアプローチは、費用対効果が高く効率的な検査ソリューションを記載しています。

目次

第1章 世界のC型肝炎検査市場の導入

  • 市場のイントロダクション
  • 調査範囲
  • 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

  • データマイニング
  • バリデーション
  • 一次資料
  • データソース一覧

第4章 C型肝炎検査の世界市場展望

  • 概要
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • ポーターのファイブフォースモデル
  • バリューチェーン分析

第5章 C型肝炎検査の世界市場：検査キット別

  • 概要
  • C型肝炎抗体検査
  • C型肝炎RNA定量検査
  • C型肝炎RNA定性検査
  • C型肝炎RIBA
  • C型肝炎ジェノタイプ
  • ウイルス負荷

第6章 C型肝炎検査の世界市場：エンドユーザー別

  • 概要
  • 病院
  • クリニック
  • 診断ラボ
  • その他

第7章 C型肝炎検査の世界市場：技術別

  • 概要
  • 免疫測定法
  • ポリメラーゼ連鎖反応（PCR）
  • その他

第8章 C型肝炎検査の世界市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • その他の欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • その他のアジア太平洋
  • その他
    • ラテンアメリカ
    • 中東・アフリカ

第9章 C型肝炎検査の世界市場の競合情勢

  • 概要
  • 各社の市場ランキング
  • 主要開発戦略

第10章 企業プロファイル

  • Siemens Healthineers
  • Abbott Laboratories
  • Roche Diagnostics
  • Bio-Rad Laboratories
  • Thermo Fisher Scientific
  • Streck
  • Illumina Inc.
  • Merck KGaA
  • Qiagen

第11章 主要開発

  • 製品上市/開発
  • 合併と買収
  • 事業拡大
  • パートナーシップと提携

第12章 付録

  • 関連調査
目次
Product Code: 36136

Hepatitis C Testing Market Size And Forecast

Hepatitis C Testing Market size was valued at USD 1.48 Billion in 2024 and is projected to reach USD 2.51 Billion by 2032, growing at a CAGR of 7.50% from 2026 to 2032.

  • Hepatitis C testing is a critical component of managing hepatitis C virus (HCV) infection. HCV is a blood-borne virus that can lead to severe liver damage if left untreated.
  • HCV infection is highly treatable with antiviral medications. Effective treatment can lead to a cure, preventing the progression of liver disease.
  • Early diagnosis and treatment are essential to prevent complications such as liver cirrhosis and liver cancer.
  • According to the Centers for Disease Control and Prevention (CDC), nearly one in three people with hepatitis C are unaware of their infection status.
  • CDC recommends universal hepatitis C screening for all adults 18 and older and all pregnant people during each pregnancy.
  • CDC recommends testing people in certain high-risk groups more frequently.

Global Hepatitis C Testing Market Dynamics

The key market dynamics that are shaping the global hepatitis C testing market include:

Key Market Drivers

  • Rising Prevalence of Hepatitis C: The increasing prevalence of Hepatitis C virus (HCV) infection is propelling the demand for testing. According to the World Health Organization, an estimated 58 million people were living with chronic HCV infection in 2023. This high prevalence underscores the urgent need for widespread testing and early diagnosis.
  • Growing Awareness and Screening Programs: Expanding awareness campaigns and screening programs are driving growth in the Hepatitis C testing market. The U.S. Centers for Disease Control and Prevention reported a 32% increase in HCV testing rates from 2020 to 2023. These initiatives are crucial for identifying undiagnosed cases and preventing further transmission.
  • Dominating Trend of Point-of-Care Testing: The shift towards rapid, point-of-care testing is dominating the Hepatitis C testing landscape. The U.S. Food and Drug Administration approved three new HCV point-of-care tests in 2023, demonstrating the growing importance of this approach. These tests enable faster diagnosis and treatment initiation.
  • Propelling Advancements in Diagnostic Technologies: Technological advancements are propelling innovations in Hepatitis C testing methods. The global molecular diagnostics market, which includes HCV testing, is projected to reach $31.8 billion by 2026, according to the National Institutes of Health. These innovations are improving test accuracy and efficiency.

Key Challenges:

  • Limited Awareness and Stigma Hindering Testing Rates: Many individuals at risk for HCV infection may not be aware of the symptoms or the importance of testing. Also, the stigma associated with HCV infection can deter individuals from seeking testing and treatment.
  • Lack of Access to Testing Facilities Hampering Early Diagnosis: Limited availability of testing facilities, particularly in underserved areas, can hinder early diagnosis of HCV infection. This can lead to delayed treatment and increased risk of complications.
  • Cost Barriers Obstructing Access to Testing and Treatment: The cost of HCV testing and treatment can be a significant barrier for many individuals, particularly in low-income communities. This can limit access to care and prevent early diagnosis and treatment.
  • Complex Regulatory Landscape Challenging Market Expansion: Navigating the regulatory landscape for HCV testing and treatment can be complex, especially for healthcare providers and manufacturers operating in multiple jurisdictions. Compliance with regulatory requirements can increase costs and hinder market expansion.

Key Trends

  • Rising Focus on Hepatitis C Elimination Efforts: Global efforts to eliminate Hepatitis C are driving increased testing initiatives. The World Health Organization reported that 21 countries were on track to achieve HCV elimination by 2030, as of 2023. These elimination programs are boosting demand for large-scale testing.
  • Growing Integration of HCV Testing in Primary Care: The integration of Hepatitis C testing into primary care settings is growing rapidly. The European Centre for Disease Prevention and Control reported a 45% increase in HCV testing at primary care facilities from 2021 to 2023. This trend is improving access to testing and early diagnosis.
  • Propelling Government Initiatives and Funding: Government initiatives and increased funding are propelling the Hepatitis C testing market forward. The U.S. Department of Health and Human Services allocated $390 million for viral hepatitis prevention and treatment in fiscal year 2024, a 15% increase from 2023. These investments are crucial for expanding testing programs.
  • Rising Adoption of Multiplex Testing Platforms: The adoption of multiplex testing platforms for simultaneous detection of multiple hepatitis viruses is rising. The global multiplex diagnostics market, including hepatitis testing, was valued at $3.9 billion in 2023, according to the National Center for Biotechnology Information. This approach offers cost-effective and efficient testing solutions.

Global Hepatitis C Testing Market Regional Analysis

Here is a more detailed regional analysis of the global hepatitis C testing market:

North America

  • North America dominates the global hepatitis C testing market, accounting for the largest share due to its advanced healthcare infrastructure and robust research ecosystem.
  • According to the National Institutes of Health (NIH), the U.S. invested $45.1 billion in biomedical research in fiscal year 2023, fueling innovation in the sector.
  • This substantial funding has led to significant advancements in areas such as gene therapy and personalized medicine.
  • For instance, in February 15, 2024, Moderna announced the expansion of its mRNA pipeline, including 15 new programs in rare diseases and oncology, further solidifying North America's leadership in hepatitis C testing.
  • The region's market dominance is also driven by a high prevalence of chronic diseases and a supportive regulatory environment.
  • The Centers for Disease Control and Prevention (CDC) reported that 6 in 10 adults in the U.S. have a chronic disease as of 2023, creating a strong demand for innovative biotechnology solutions.
  • This demand is met by cutting-edge research and development efforts from industry leaders.
  • For instance, on September 8, 2023, Pfizer received FDA approval for its gene therapy treatment for hemophilia B, marking a significant milestone in hepatitis C testing applications and reinforcing North America's position at the forefront of the global market.

Asia Pacific

  • Asia Pacific is poised to emerge as the fastest-growing region in the global hepatitis C testing market during the forecast period, driven by the high prevalence, coupled with improving healthcare infrastructure and rising awareness, thus driving the market growth.
  • According to the World Health Organization's Western Pacific Region office, an estimated 39 million people were living with chronic hepatitis C in the region as of 2023, highlighting the urgent need for enhanced testing efforts.
  • On March 8, 2024, Abbott Laboratories announced the launch of its new rapid HCV test in India, aiming to increase access to quick and accurate diagnosis in resource-limited settings.
  • The region's growth is further fueled by government initiatives and increasing healthcare expenditure. China's National Health Commission reported a 40% increase in hepatitis C screening rates from 2021 to 2023, demonstrating a strong commitment to disease control.
  • also, the emerging economies are adopting advanced testing technologies to improve diagnostic accuracy and efficiency.
  • On November 15, 2023, Roche Diagnostics partnered with the Malaysian Ministry of Health to provide 1 million HCV tests as part of a nationwide elimination program, showcasing the collaborative efforts between industry leaders and governments to combat hepatitis C in the Asia Pacific region.

Global Hepatitis C Testing Market: Segmentation Analysis

The Global Hepatitis C Testing Market is segmented based on Test Kits, Technique, End-User, and Geography.

Hepatitis C Testing Market, By Test Kits

  • Hepatitis C Antibody Test
  • Hepatitis C RNA Quantitative Test
  • Hepatitis C RNA Qualitative Test
  • Hepatitis C RIBA
  • Hepatitis C Genotype
  • Viral Load

Based on Test Kits, the Global Hepatitis C Testing Market is bifurcated into Hepatitis C Antibody Test, Hepatitis C RNA Quantitative Test, Hepatitis C RNA Qualitative Test, Hepatitis C RIBA, Hepatitis C Genotype, Viral Load. The hepatitis C RNA quantitative test segment is currently dominating the global hepatitis C testing market, driven by its ability to accurately measure the viral load of HCV infection. However, the hepatitis C genotype test segment is experiencing rapid growth, as understanding the HCV genotype is essential for selecting the most effective treatment regimen.

Hepatitis C Testing Market, By Technique

  • Immunoassays
  • Polymerase Chain Reaction (PCR)
  • Others

Based on Technique, the Global Hepatitis C Testing Market is bifurcated into Immunoassays, Polymerase Chain Reaction (PCR), Others. The immunoassay segment is currently dominating the global hepatitis C testing market, owing to its established reputation for simplicity, affordability, and high sensitivity in detecting hepatitis C antibodies. However, polymerase chain reaction (PCR) segment is experiencing rapid growth, driven by its superior accuracy and ability to directly detect the hepatitis C virus, making it a valuable tool for early diagnosis and treatment monitoring.

Hepatitis C Testing Market, By End-User

  • Hospitals
  • Clinics
  • Diagnostic Laboratories
  • Others

Based on End-User, the Global Hepatitis C Testing Market is bifurcated into Hospital and Clinics, Diagnostic Laboratories, Others. The hospitals segment is currently dominating the global hepatitis C testing market, driven by the high volume of patients seeking testing and treatment in these facilities. However, the diagnostic laboratories segment is experiencing rapid growth, as healthcare providers increasingly rely on specialized laboratories for accurate and efficient testing services.

Hepatitis C Testing Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world

Based on Geography, the Global Hepatitis C Testing Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America dominates the global hepatitis C testing market, accounting for the largest share due to its advanced healthcare infrastructure and robust research ecosystem. However, Asia Pacific is poised to emerge as the fastest-growing region in the global hepatitis C testing market during the forecast period, driven by the high prevalence, coupled with improving healthcare infrastructure and rising awareness thus driving the market growth.

Key Players

The "Global Hepatitis C Testing Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Abbott (U.S.), Bio-Rad Laboratories Inc., QIAGEN, Bayer AG, OraSure Technologies, Inc., Sysmex Corporation, Meridian Bioscience, Biogate Laboratories Ltd.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Hepatitis C Testing Market Key Developments

  • In February 2023, the Pune-based company Mylab Discovery Solutions declared that it would be launching three new rapid tests to identify STIs in a timely manner. STIs are a serious problem since, according to WHO estimates, there will be one million STI cases worldwide each day.
  • In September 2022, An IVD company called J Mitra unveiled the HCV Gen 4 Ag & Ab Microlisa, a fourth-generation Elisa-based HCV test. The purpose of the kit is to screen blood donors in order to identify and eliminate blood units that are contaminated. Hepatitis C can also be clinically diagnosed with this kit.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL HEPATITIS C TESTING MARKET

  • 1.1 Introduction of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL HEPATITIS C TESTING MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL HEPATITIS C TESTING MARKET, BY TEST KITS

  • 5.1 Overview
  • 5.2 Hepatitis C Antibody Test
  • 5.3 Hepatitis C RNA Quantitative Test
  • 5.4 Hepatitis C RNA Qualitative Test
  • 5.5 Hepatitis C RIBA
  • 5.6 Hepatitis C Genotype
  • 5.7 Viral Load

6 GLOBAL HEPATITIS C TESTING MARKET, BY END-USERS

  • 6.1 Overview
  • 6.2 Hospitals
  • 6.3 Clinics
  • 6.4 Diagnostic Laboratories
  • 6.5 Others

7 GLOBAL HEPATITIS C TESTING MARKET, BY TECHNOLOGY

  • 7.1 Overview
  • 7.2 Immunoassays
  • 7.3 Polymerase Chain Reaction (PCR)
  • 7.4 Others

8 GLOBAL HEPATITIS C TESTING MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East and Africa

9 GLOBAL HEPATITIS C TESTING MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Siemens Healthineers
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Abbott Laboratories
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Roche Diagnostics
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Bio-Rad Laboratories
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Thermo Fisher Scientific
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Streck
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Illumina Inc.
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Merck KGaA
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Qiagen
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12 Appendix

  • 12.1 Related Research